Healthcare distributor Cencora (NYSE: COR) fell short of the market’s revenue expectations in Q4 CY2025, but sales rose 5.5% year on year to $85.93 billion. Its non-GAAP profit of $4.08 per share was 1% above analysts’ consensus estimates.

Is now the time to buy COR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Cencora's fourth quarter was marked by a negative market reaction, as revenue missed Wall Street’s expectations despite year-over-year growth. Management attributed performance to continued growth in its U.S. healthcare solutions, particularly specialty pharmaceuticals and new contributions from recent acquisitions. CEO Robert Mauch emphasized the impact of enhanced operational capabilities and highlighted the integration of Retina Consultants of America (RCA) and the completion of the OneOncology acquisition as pivotal to driving both revenue and operating income growth. The quarter was also shaped by strong sales of GLP-1 medications and the company’s ongoing focus on supporting specialty care providers.

Looking ahead, Cencora’s guidance is shaped by expectations for operational synergies from recent MSO (management services organization) acquisitions, including OneOncology, and ongoing specialty segment momentum. Management believes these platforms will accelerate clinical research capabilities and expand patient access to modern treatments. CFO James Cleary noted, “The OneOncology platform is well-positioned, high-performing, and will be a meaningful contributor to Cencora’s operating income both in 2026 and in our long-term plans.” However, management also highlighted potential headwinds from increased financing costs and competitive pressures in core segments.

Key Insights from Management’s Remarks

Management credited recent performance to operational efficiency in specialty pharmaceuticals, strong underlying demand, and the strategic acquisition of OneOncology, which is expected to create long-term value through enhanced MSO capabilities.

• MSO platform expansion: The acquisitions of RCA and OneOncology are central to Cencora’s strategy, enabling broader physician support services, advanced clinical research, and stronger relationships with both providers and pharmaceutical companies.
• Specialty utilization trends: Management highlighted sustained high demand in specialty pharmaceuticals, particularly in the U.S. healthcare solutions segment, with strong volumes among health systems and physician practices fueling operating income growth.
• Operational excellence and technology: The company is investing in technology and analytics to streamline delivery of pharmaceutical services, supporting tailored solutions for customers and improving operational margins.
• International segment dynamics: While international revenue grew, operating income faced timing-related headwinds from manufacturer price adjustments in certain developing markets, which management expects to normalize in coming quarters.
• Portfolio realignment and focus: Cencora is actively evaluating its business mix, prioritizing growth-oriented investments, and considering strategic alternatives for less aligned segments, as seen with ongoing assessment of its animal health and consulting businesses.

Drivers of Future Performance

Cencora’s outlook is anchored in leveraging recent MSO acquisitions, ongoing specialty growth, and operational optimization, but faces challenges from rising financing costs and evolving market dynamics.

• MSO integration and scale: Management expects the combination of RCA and OneOncology to generate both immediate and long-term operating income benefits, with the rollout of shared capabilities in clinical trials and revenue cycle management driving physician and biopharma engagement.
• Specialty segment leadership: Continued growth in specialty pharmaceuticals, especially through expanded partnerships with health systems and physician practices, is projected to remain a primary driver of revenue and profitability.
• Cost and margin pressures: Elevated interest expenses due to recent acquisitions and ongoing headwinds from competitive customer losses and pricing dynamics in certain international markets present risks to margin performance in the coming quarters.

Catalysts in Upcoming Quarters

Looking forward, the StockStory team is monitoring (1) how effectively Cencora integrates and scales its MSO acquisitions to drive specialty platform synergies, (2) the extent of operating income improvement in international markets as timing headwinds recede, and (3) the company’s progress on realigning its business portfolio for long-term growth. Continued execution in specialty pharmaceuticals and the ability to manage financing costs will also be important signposts.

Cencora currently trades at $330.48, down from $361.75 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.